Patents by Inventor Sophie VIAUD

Sophie VIAUD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
    Patent number: 11344586
    Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: May 31, 2022
    Assignees: INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
    Inventors: Laurence Zitvogel, Ivo Gomperts Boneca, Patricia Lepage, Sophie Viaud, Romain Daillere
  • CAR T CELL METHODS AND CONSTRUCTS
    Publication number: 20220090132
    Abstract: The disclosure provides non-replicating viral vectors (RNV) for adoptive cell therapy. The RNVs can deliver chimeric antigen receptors to immune cells (e.g., T-Cells) in vivo.
    Type: Application
    Filed: January 6, 2020
    Publication date: March 24, 2022
    Inventors: Douglas J. Jolly, Joan M. Robbins, Amy H. Lin, Derek G. Ostertag, Cornelia Bentley, Sophie Viaud
  • CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF
    Publication number: 20220073597
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Application
    Filed: August 30, 2021
    Publication date: March 10, 2022
    Inventors: Travis S. YOUNG, Leonard PRESTA, David RODGERS, Eric HAMPTON, Timothy WRIGHT, Peter G. SCHULTZ, Eduardo LABORDA, Elvira KHIALEEVA, Sophie VIAUD
  • Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
    Patent number: 11174306
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: November 16, 2021
    Assignee: The Scripps Research Institute
    Inventors: Travis S. Young, Leonard Presta, David Rodgers, Eric Hampton, Timothy Wright, Peter G. Schultz, Eduardo Laborda, Elvira Khialeeva, Sophie Viaud
  • MICROBIOTA COMPOSITION, AS A MARKER OF RESPONSIVENESS TO CHEMOTHERAPY, AND USE OF MICROBIAL MODULATORS (PRE-, PRO- OR SYNBIOTICS) FOR IMPROVING THE EFFICACY OF A CANCER TREATMENT
    Publication number: 20200360449
    Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
    Type: Application
    Filed: April 21, 2020
    Publication date: November 19, 2020
    Inventors: Laurence ZITVOGEL, Ivo GOMPERTS BONECA, Patricia LEPAGE, Sophie VIAUD, Romain DAILLERE
  • Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
    Patent number: 10646521
    Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: May 12, 2020
    Assignees: INSTITUT GUSTAVE ROUSSY, UNIVERSITÉ PARIS—SACLAY, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT DE LA RECHERCHE AGRONOMIQUE
    Inventors: Laurence Zitvogel, Ivo Gomperts Boneca, Patricia Lepage, Sophie Viaud, Romain Daillere
  • CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF
    Publication number: 20190359697
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Application
    Filed: October 19, 2017
    Publication date: November 28, 2019
    Inventors: Travis S. YOUNG, Leonard PRESTA, David RODGERS, Eric HAMPTON, Timothy WRIGHT, Peter G. SCHULTZ, Eduardo LABORDA, Elvira KHIALEEVA, Sophie VIAUD
  • MICROBIOTA COMPOSITION, AS A MARKER OF RESPONSIVENESS TO CHEMOTHERAPY, AND USE OF MICROBIAL MODULATORS (PRE-, PRO- OR SYNBIOTICS) FOR IMPROVING THE EFFICACY OF A CANCER TREATMENT
    Publication number: 20160303172
    Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
    Type: Application
    Filed: November 21, 2014
    Publication date: October 20, 2016
    Inventors: Laurence ZITVOGEL, Ivo GOMPERTS BONECA, Patricia LEPAGE, Sophie VIAUD, Romain DAILLERE